期刊文献+

PICU临床药师参与抗感染药物治疗案例分析 被引量:1

Case Study:Clinical Pharmacists Participating in Anti-infection Drug Treatment in PICU
原文传递
导出
摘要 目的探讨临床药师在儿童重症监护病房抗感染药物治疗中的作用。方法通过临床药师参与1例感染性休克患儿抗感染药物治疗过程,与临床医师共同制订治疗方案,监护患者用药全过程,针对患者病情变化提出治疗方案调整。结果临床药师在抗感染治疗进程中,提出监测利奈唑胺血药浓度等建议被临床采纳,充分体现以药动学和药效学理论指导个体化给药。结论临床药师参与医疗团队,协助临床医师调整药物治疗方案,有利于提高药物治疗效果。 OBJECTIVE To investigate the role of clinical pharmacists in anti-infection drug treatment in PICU(Pediatric Intensive Care Unit). METHODS The clinical pharmacists participated in the anti-infection drug treatment of a child patient, formulated the treatment plan together with the clinical doctors and supervised the whole process of treatment for the patient, then adjusted treatment plan according to the patient's changed condition. RESULTS During the anti-infection treatment, clinical pharmacists provided suggestion such as monitoring the plasma concentration of linezolid that were adopted, which reflected applying of pharmacokinetics and pharmacodynamics theories to guide individualized medicine administration. CONCLUSIONS Clinical pharmacists participation in the clinical treatment and corporation with the clinical doctors to adjust the treatment plan can improve the effectiveness of drug treatment.
出处 《中国现代应用药学》 CAS CSCD 2014年第2期228-230,共3页 Chinese Journal of Modern Applied Pharmacy
基金 浙江省医学会临床科研基金(2011ZYC-A23)
关键词 临床药师 儿童重症监护病房 抗感染 药学监护 clinical pharmacist pediatric intensive care unit anti-infection pharmaceutical care
  • 相关文献

参考文献4

二级参考文献25

  • 1林东昉,吴菊芳,张婴元,郑经川,缪竞智,郑丽叶,盛瑞媛,周新,沈华浩,吴卫红,周乐,汪复.利奈唑胺与万古霉素治疗革兰阳性菌感染的随机、双盲、对照、多中心临床试验[J].中国感染与化疗杂志,2009,9(1):10-17. 被引量:56
  • 2中华医学会儿科学会急救学组.第四届全国小儿急救医学研讨会纪要[J].中华儿科杂志,1995,33:370-370.
  • 3TAYLOR JJ, WILSON JW, ESTES LL. Linezolid and serotonergic drug interactions: a retrospective survey [J]. Clin Infect Dis, 2006, 43(2): 180-187.
  • 4TUBAU F , FERNANDEZ-ROBLAS R, LINARES J, et al. In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods [J] . J Antimicrob Chemother, 2001, 48 (4): 675-680.
  • 5PATEL U, YAN YP, HOBBS FW Jr, et al. Oxazolidinones mechanism of action: inhibition of the first peptide bond formation[J].J Biol Chem, 2001, 276(40) : 37199-37205.
  • 6TAN TQ. Update on the use of linezolid : a pediatric perspective [J]. Pediatr Infect Dis J, 2004, 23(10): 955-956.
  • 7BISHOP E, MELVANI S, HOWDEN BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients [J]. Antimicrob Agents Chemother, 2006, 50(4) : 1599-1602.
  • 8SAIMAN L, GOLDFARB J, KAPLAN SA, et al. Safety and tolerability of linezolid in children [J]. Pediatr Infect Dis J, 2003, 22(9 Suppl): S193-S200.
  • 9Centers for Disease Contrail and Prevention. Guidelines for the prevention of intravascular catheter-related infections [ J ]. Morb Mortal Wkly Rep , 2002, 51 (10):1-29.
  • 10JONES R N, FRITSCHE T R, SADER H S, et al. ZyvoxaAnnual Appraisal of Potency and Spectrum Program Results fur 2006: an aetivily and spectrum analysis of linezolid using clinical isolates from 16 countries [ J ]. Diagn Microbiol Infect Dis, 2007, 59 ( 2 ) : 199 -209.

共引文献21

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部